Arbutus Biopharma. has filed a patent for stable lipid particles with a non-lamellar structure containing therapeutic agents, specifically nucleic acid-lipid particles (SNALP). The invention focuses on methods of making and delivering these particles. GlobalData’s report on Arbutus Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Arbutus Biopharma Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arbutus Biopharma, Peptide pharmacophores was a key innovation area identified from patents. Arbutus Biopharma's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Lipid particles for stable delivery of therapeutic agents

Source: United States Patent and Trademark Office (USPTO). Credit: Arbutus Biopharma Corp

The patent application (Publication Number: US20240035030A1) describes a composition comprising nucleic acid-lipid particles, with each particle containing a nucleic acid, a cationic lipid with diastereomers, a non-cationic lipid, and a conjugated lipid that prevents particle aggregation. The majority of these particles are electron-dense, with specific details provided for the composition, including the type of nucleic acid (RNA or mRNA), the structure of the cationic lipid, and the presence of a polyethyleneglycol (PEG)-lipid conjugate to inhibit aggregation.

Furthermore, the patent application outlines various aspects of the composition, such as the structure of the electron-dense particles, the encapsulation of nucleic acid within the particles, the size range of the particles, and the lipid:nucleic acid ratio. Additionally, the application includes claims related to the pharmaceutical composition containing the described particles and a method for introducing a therapeutic agent into a cell or for in vivo delivery of a therapeutic agent by administering the composition to a mammal. These claims highlight the potential applications of the composition in the field of medicine for targeted delivery of therapeutic agents.

To know more about GlobalData’s detailed insights on Arbutus Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies